lysergide tartrate
lysergide · DT120 · DT120 ODT Small Molecule Target: 5-HT2A
Definium Therapeutics
Most recent annual filing: 2026-02-15
- DT402 R-MDMA interim2026DT402 R-MDMA interim, 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
R(-)-MDMA
DT402Biotech Distilled coverage (10)
- 2026-09-15 UPDATE: Definium (DFTX) - Panorama Hits, And the Unblinding Elephant Finally Gets Answered 🔒 Paid
- 2026-09-08 UPDATE: Definium (DFTX) - A Second Breakthrough, And a Stock That Keeps Bleeding 🔒 Paid
- 2026-08-13 UPDATE: Definium (DFTX) - Voyage Hits, And the Stock Sells Off Anyway 🔒 Paid
- 2026-08-07 UPDATE: Definium (DFTX) - Voyage Lands Next Week, And They Quietly Bought Out Their Royalty 🔒 Paid
- 2026-06-24 UPDATE: Definium (DFTX) - The Raise Got Upsized, And The Greenshoe Cleared Same-Day 🔒 Paid
- 2026-06-22 UPDATE: Definium (DFTX) - Emerge Hits, And They Hit the Market 🔒 Paid
- 2026-05-08 UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party 🔒 Paid
- 2026-04-27 UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper 🔒 Paid
- 2026-02-28 UPDATE: Definium (DFTX) Q4 Financial Update 🔒 Paid
- 2026-01-14 Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.